Catalent (CTLT) Stock Price
Catalent Price
Over the last 15 years Catalent grew revenue by 7.9% annually, reaching 4.38 B USD. Earnings per share have grown at 46.7% per year over the last 8 years. For Catalent, the net margin of -23.8% is down versus 5.6% a few years ago. The consensus 12-month price target for Catalent is 64.77 USD, about 2.0% above where the stock trades today. Of 14 analysts, 0 rate the stock a buy — an overall Hold consensus.
Catalent stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Catalent over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Catalent stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Catalent's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Catalent Price |
|---|
Catalent Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Catalent Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.83 | 1.85 | 2.08 | 2.46 | 2.52 | 3.09 | 4.00 | 4.83 | 4.28 | 4.38 | 4.63 | 5.00 | 5.42 | 5.82 | 6.29 | 6.83 |
| 0.16 | 0.98 | 12.28 | 18.70 | 2.23 | 22.88 | 29.22 | 20.76 | -11.43 | 2.46 | 5.71 | 7.86 | 8.45 | 7.40 | 8.13 | 8.49 |
| 33.61 | 31.76 | 31.52 | 30.53 | 31.97 | 31.77 | 33.82 | 33.97 | 24.79 | 21.75 | 21.75 | 21.75 | 21.75 | 21.75 | 21.75 | 21.75 |
| 0.62 | 0.59 | 0.65 | 0.75 | 0.81 | 0.98 | 1.35 | 1.64 | 1.06 | 0.95 | 1.01 | 1.09 | 1.18 | 1.27 | 1.37 | 1.48 |
| 0.26 | 0.22 | 0.23 | 0.27 | 0.06 | 0.14 | 0.83 | 0.73 | -0.16 | -0.75 | 0.24 | 0.26 | 0.29 | 1.20 | – | – |
| 14.15 | 11.74 | 11.28 | 11.00 | 2.42 | 4.62 | 20.64 | 15.04 | -3.65 | -17.10 | 5.27 | 5.27 | 5.26 | 20.64 | – | – |
| 0.21 | 0.11 | 0.11 | 0.08 | 0.14 | 0.17 | 0.59 | 0.50 | -0.23 | -1.04 | 0.21 | 0.32 | 0.43 | 0.56 | 0.71 | 0.88 |
| 1,225.00 | -47.64 | -1.80 | -23.85 | 65.06 | 26.28 | 238.15 | -14.70 | -146.49 | 349.57 | -120.23 | 50.71 | 35.85 | 30.32 | 25.75 | 23.59 |
| 125.83 | 126.41 | 132.98 | 146.66 | 147.69 | 169.00 | 178.85 | 181.00 | 182.00 | 182.00 | 182.00 | 182.00 | 182.00 | 182.00 | 182.00 | 182.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Catalent generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Catalent retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Catalent's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Catalent has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Catalent's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Catalent stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Catalent Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Catalent business model & stock analysis
Catalent SWOT Analysis
Strengths
Catalent Inc has a strong global presence, with operations in various countries, allowing it to tap into diverse markets and customer base.
The company has a wide range of capabilities and expertise in pharmaceutical and biotechnology services, including drug development, clinical manufacturing, packaging, and supply chain management.
Catalent Inc has established strong relationships with key pharmaceutical and biotech companies, resulting in long-term partnerships and repeat business.
Weaknesses
The company may face high dependence on a few major clients, which poses the risk of reduced revenues and profitability if these clients shift their business elsewhere.
Catalent Inc's reliance on a complex supply chain network can lead to potential disruptions and challenges in managing inventory and distribution.
Limited brand recognition compared to some competitors may impact Catalent Inc's ability to attract new customers and gain market share.
Opportunities
Growing demand for pharmaceutical and biotechnology services, driven by the increasing need for personalized medicine and advancements in drug development, presents significant growth opportunities for Catalent Inc.
Expansion into emerging markets, such as Asia and Latin America, where the demand for pharmaceutical and biotech services is increasing, can help Catalent Inc diversify its customer base and revenue streams.
Catalent Inc can leverage its expertise in drug delivery technologies to tap into the growing market for specialty pharmaceuticals and targeted therapies.
Threats
Intense competition within the pharmaceutical and biotech services industry poses a threat to Catalent Inc's market share and pricing power.
Regulatory changes and stringent quality requirements in the pharmaceutical industry can increase compliance costs and pose challenges for Catalent Inc's operations.
Economic downturns or fluctuations in healthcare spending can impact the demand for pharmaceutical and biotech services, potentially affecting Catalent Inc's financial performance.
Catalent Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Catalent Segments
Catalent Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
Catalent Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Catalent Revenue by Segment (3/3)
3 Years
5 Years
10 Years
Max
Details
Catalent Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Catalent Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Catalent historical P/E ratio, EBIT multiple, and P/S ratio
Catalent annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Catalent shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Catalent forecasts and price targets in August 2026
Analyst Price Targets 2026Catalent Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 9/24/2024 | Downgrade | OutperformNeutral | – | |
| 7/11/2024 | Maintained | Sector Perform | 52 | |
| 6/28/2024 | Maintained | Equal Weight | 33 | |
| 4/4/2024 | Maintained | Equal Weight | – | |
| 2/20/2024 | Maintained | Sector Perform | 52 | |
| 2/6/2024 | Downgrade | BuyNeutral | 51 | |
| 2/6/2024 | Downgrade | OverweightEqual Weight | – | |
| 2/6/2024 | Downgrade | OutperformSector Perform | 52 | |
| 1/25/2024 | Maintained | Equal Weight | 33 | |
| 11/16/2023 | Maintained | Equal Weight | 56 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Catalent Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/13/2024 | 0.06USD | - | 1.08 BUSD | - | 2025 Q1 |
| 5/17/2024 | 0.24USD | - | 1.14 BUSD | - | 2024 Q3 |
| 2/5/2024 | -0.03USD | - | 1.04 BUSD | - | 2024 Q2 |
| 8/28/2023 | 1.28USD | - | 1.36 BUSD | - | 2023 Q4 |
| 5/1/2023 | 0.96USD | - | 1.22 BUSD | - | 2023 Q3 |
| 1/30/2023 | 0.69USD | - | 1.12 BUSD | - | 2023 Q2 |
| 11/1/2022 | 0.57USD | - | 1.09 BUSD | - | 2023 Q1 |
| 8/29/2022 | 1.17USD | - | 1.35 BUSD | - | 2022 Q4 |
| 5/3/2022 | 0.95USD | - | 1.24 BUSD | - | 2022 Q3 |
| 2/1/2022 | 0.85USD | - | 1.16 BUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Catalent stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Catalent shareholder structure
| % | Name |
|---|---|
2.30188% | |
0.49613% | |
0.15964% | |
0.15180% | |
0.08042% | |
0.07231% |
Catalent Beneficial Ownership Filings (SEC 13D/G)
Catalent Executives and Management Board
22 members · avg. age 59 · 23 % women
Mr. Alessandro Maselli (51)
President, Chief Executive Officer, Director · since 2016
6.58 M USD
Management
Dr. Aristippos Gennadios (58)
Group President - Pharma and Consumer Health
Mr. Ricky Hopson (48)
President, Division Head for BioProduct Delivery and Chief of Staff
Mr. Matti Masanovich (51)
Chief Financial Officer, Senior Vice President
Mr. David Mcerlane (50)
Group President - Catalent's Biologics segment
Ms. Lisa Evoli (54)
Chief Human Resource Officer, Senior Vice President
Mr. Joseph Ferraro (46)
Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary
Board of Directors
Mr. J. Martin Carroll (73)
Independent Director · since 2015
Mr. John Greisch (68)
Executive Chairman of the Board · since 2018
Mr. Jack Stahl (70)
Lead Independent Director
Mr. Gregory Lucier (59)
Independent Director
Ms. Rosemary Crane (63)
Independent Director
Dr. Donald Morel (66)
Independent Director
Catalent Supply Chain
Catalent Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.92 | 0.86 | 0.86 | ||
| 2 | 0.89 | 0.88 | 0.80 | ||
| 3 | 0.82 | 0.82 | 0.77 | ||
| 4 | Horizon Therapeutics Public Limited Company | 0.34 | 0.63 | 0.75 | |
| 5 | 0.77 | 0.78 | 0.64 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | GlaxoSmithKline plc | -0.56 | -0.61 | — | |
| 2 | 0.83 | 0.29 | -0.64 | ||
| 3 | 0.69 | 0.53 | -0.56 | ||
| 4 | 0.63 | 0.37 | -0.47 | ||
| 5 | 0.44 | 0.08 | -0.34 |
Frequently asked questions about Catalent
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Analysts currently set an average price target of 64.77 USD for the Catalent stock (median: 64.77 USD), implying +2.0 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Catalent stock: 0 recommend buying, 11 holding and 3 selling. For 2026, analysts expect Catalent to generate revenue of 5.00 B USD and earnings per share of 1.75 USD.
Converted at the current exchange rate, the Catalent share trades at 55.15 EUR (63.48 USD).
The Catalent share (CTLT) is listed on 4 stock exchanges, including: NYSE (CTLT), Frankfurt (0C8.F), München (0C8.MU), SIX (Zürich) (0C8.SW).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
The expected revenue of Catalent is 5.00 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Catalent is 318.65 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Catalent is currently 36.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Catalent stock.
The price-to-sales ratio (P/S) of Catalent is currently 2.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Catalent stock.
The Eulerpool Quality Score for Catalent is 2/10.
The ISIN of Catalent is US1488061029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Catalent is A112H2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Catalent is CTLT. The ticker symbol is used to trade Catalent shares on the stock exchange.
Catalent paid dividends every year for the past 0 years.
Catalent is assigned to the 'Health' sector.
The dividends of Catalent are distributed in USD.
Catalent stock
Catalent Peer Group
Catalent Ticker
Catalent FIGI
All fundamentals and in-depth analysis of Catalent
Our stock analysis for Catalent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.